Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
121
NCT04458805
Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 10, 2020
Completion: Oct 21, 2020
NCT04862741
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
Start: May 5, 2021
Completion: Oct 5, 2022
NCT06308159
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
Phase: Phase 1/2
Start: May 11, 2024
Completion: Aug 1, 2027
NCT06288230
An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy
Start: Oct 20, 2024
Completion: Oct 30, 2027